Sale

Biobanking Market

Global Biobanking Market Size, Share, Analysis, Forecast: By Material: Population-based Biobanks, Disease-based Biobanks, Academic Biobanks, Hospital-based Biobanks, Commercial Biobanks; By Sample Type: Blood Products, Others; By Application; By Ownership; By Source; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Global Biobanking Market Outlook

The global biobanking market size was valued at USD 72.1 billion in 2023, driven by the increased genomic research activities aimed at discovering innovative therapeutic interventions across the globe. The market is expected to grow at a CAGR of 6.89% during the forecast period of 2024-2032, with the values likely to rise from USD 76.9 billion in 2024 to USD 131.1 billion by 2032.

 

Global Biobanking Market Overview

Biobanks form an essential resource in medical research. They are a type of biorepository to store and manage biological samples. With the growing interest and research on genomics and personalized medicine, the market for biobanks is expected to witness a surge.

 

The substantial financial support from both private and government sectors is aiding in improving the infrastructure and database capabilities of biobanks. In October 2023 , the United Kingdom Biobank received EUR 16 million, along with another EUR 25 million contribution from the government, to secure a total funding of around EUR 50 million. These investments will aid in the expansion of the biobank’s health data, accelerating research and enabling technological advancements such as the integration of artificial intelligence (AI) to analyze data efficiently. Such financial contributions from public and private organizations will facilitate the biobanking market growth in the forecast period.

 

The market is also driven by the expansion of the biotechnology sector and the rise in healthcare expenditure to improve patient outcomes. Further, the demand for biobanks is propelled by the rise in the prevalence of chronic diseases and the need for effective treatments.

 

Global Biobanking Market Trends

Key Trends Description
Increasing Adoption of Precision Medicine The market is witnessing a surge in the adoption of precision medicine approaches, where genetic and molecular information is utilized to customize medical treatments for individual patients. This trend drives the need for biobanking solutions capable to store and manage diverse biological samples.
Emphasis on Data Integration and Standardization With the growing volume and complexity of biological and clinical data, there is an increased emphasis on data integration and standardization within biobanking operations. This ensures data quality and interoperability.
Expansion of Disease-specific Biobanks There is a significant expansion in the establishment of disease-specific biobanks focused on collecting samples from individuals afflicted with certain diseases. These specialized biobanks enable targeted research into disease mechanisms, biomarker discovery, and the development of personalized therapies.
Integration of Advanced Technologies Advanced technologies such as automation, robotics, and artificial intelligence (AI) are increasingly being integrated into biobanking workflows to enhance efficiency, accuracy, and scalability. 

 

Global Biobanking Market Segmentation

Market Breakup by Material

  • Population-based Biobanks
  • Disease-based Biobanks
  • Academic Biobanks
  • Hospital-based Biobanks
  • Commercial Biobanks

 

The biobanking market report includes a breakup based on materials as well. It includes population-based biobanks, disease-based biobanks, academic biobanks, hospital-based biobanks, and commercial biobanks. These biobanks serve different purposes such as population-based biobanks collect samples from large groups of individuals for epidemiological and population studies.

 

Market Breakup by Sample Type

  • Blood Products
  • Human Tissues
  • Nucleic Acids
  • Cell Lines
  • Biological Fluids
  • Others

 

By sample type, the market is divided into blood products, human tissues, nucleic acids, cell lines, biological fluids, and others. This market segment reveals the range of materials stored in biobanks for research and clinical applications.

 

Market Breakup by Application

  • Drug Discovery and Development
  • Personalized Medicine
  • Regenerative Medicine
  • Clinical Research
  • Forensics
  • Others

 

Applications of the market include drug discovery and development, personalized medicine, regenerative medicine, clinical research, forensics, and others. The increased application of biobanks across various sectors has fuelled the biobanking market demand.

 

Market Breakup by Ownership

  • Public Biobanks
  • Private Biobanks
  • Hybrid Biobanks

 

The market breakup by ownership in the global biobanking market includes public biobanks, private biobanks, and hybrid biobanks. Public biobanks are operated and funded by governmental or non-profit organizations whereas private biobanks are owned and operated by commercial organizations or individuals. Hybrid biobanks have both public and private ownership structures to collect and manage samples for various purposes.

 

Market Breakup by Source

  • Human Biobanks
  • Animal Biobanks
  • Plant Biobanks

 

The market segmentation by source includes human biobanks, animal biobanks, and plant biobanks. This segmentation provides the range of sources utilized in biobanking across different scientific domains.

 

Market Breakup by End User

  • Biopharmaceutical Companies
  • Research and Academic Institutes
  • Hospitals
  • Contract Research Organizations (CROs)
  • Others

 

By the end user, the biobanking market share includes biopharmaceutical companies, research and academic institutes, hospitals, contract research organizations (CROs), and others. Biopharmaceutical companies cover a significant portion of the market segment by utilizing biobank samples for drug discovery, development, and clinical trials.

 

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

The market report will cover the leading regional markets such as North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America holds a high market value, driven by intensive research initiatives, and robust regulatory frameworks. The regional market also has a strong presence of academic and research institutions as well as leading biopharmaceutical companies to support biobanking initiatives.

 

Global Biobanking Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Thermo Fisher Scientific Inc.
  • Brooks Automation, Inc.
  • Qiagen N.V.
  • Tecan Group Ltd.
  • Hamilton Company
  • Chart Industries, Inc.
  • PHC Holdings Corporation
  • Becton, Dickinson and Company (BD)
  • Merck KGaA
  • Panasonic Healthcare Holdings Co., Ltd.
  • STEMCELL Technologies Inc.
  • Lifenet Health
  • Promega Corporation
  • reiner Bio-One International GmbH
  • Lonza Group AG

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Material
  • Sample Type
  • Application
  • Ownership
  • Source
  • End User
  • Region
Breakup by Material
  • Population-based Biobanks
  • Disease-based Biobanks
  • Academic Biobanks
  • Hospital-based Biobanks
  • Commercial Biobanks
Breakup by Sample Type
  • Blood Products
  • Human Tissues
  • Nucleic Acids
  • Cell Lines
  • Biological Fluids
  • Others
Breakup by Application
  • Drug Discovery and Development
  • Personalized Medicine
  • Regenerative Medicine
  • Clinical Research
  • Forensics
  • Others
Breakup by Ownership
  • Public Biobanks
  • Private Biobanks
  • Hybrid Biobanks
Breakup by Source
  • Human Biobanks
  • Animal Biobanks
  • Plant Biobanks
Breakup by End User
  • Biopharmaceutical Companies
  • Research and Academic Institutes
  • Hospitals
  • Contract Research Organizations (CROs)
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Thermo Fisher Scientific Inc.
  • Brooks Automation, Inc.
  • Qiagen N.V. 
  • Tecan Group Ltd.
  • Hamilton Company
  • Chart Industries, Inc.
  • PHC Holdings Corporation
  • Becton, Dickinson and Company (BD) 
  • Merck KGaA
  • Panasonic Healthcare Holdings Co., Ltd.
  • STEMCELL Technologies Inc.
  • Lifenet Health
  • Promega Corporation
  • Greiner Bio-One International GmbH
  • Lonza Group AG

 

Key Queries Solved in the Global Biobanking Market Report 

  • How is the market landscape expected to evolve in the forecast period? 
  • What are the major trends influencing the market? 
  • What are the significant drivers, opportunities, and restraints in the market? 
  • What will be the effect of each driver, challenge, and opportunity on the market? 
  • Which regional market is poised to lead the market share in the forecast period? 
  • Which regional market will experience expedited growth during the forecast period? 
  • Which material type of biobanks will fuel market growth? 
  • Which sample type is anticipated to propel the biobanking market value? 
  • Which ownership type of biobanks is expected to dominate the market segment?
  • Which source type will witness high demand in coming years?
  • Which applications are expected to impact the growth of the market significantly?
  • What technological advancements and innovations are influencing the market?
  • Which segment has the highest impact on the market size? 
  • How are partnerships, collaborations, and mergers & acquisitions shaping the market dynamics?

Biobanking Market Report Snapshots

Biobanking Market Size

Biobanking Market Trends

Biobanking Companies

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Global Biobanking Market Overview 

    3.1    Global Biobanking Market Historical Value (2017-2023) 
    3.2    Global Biobanking Market Forecast Value (2024-2032)
4    Global Biobanking Market Landscape*
    4.1    Global Biobanking: Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Biobanking: Product Landscape
        4.2.1    Analysis by Material    
        4.2.2    Analysis by Sample Type
5    Global Biobanking Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
        5.2.1    Strengths
        5.2.2    Weaknesses
        5.2.3    Opportunities
        5.2.4    Threats
    5.3    Porter’s Five Forces Model
        5.3.1    Bargaining Power of Suppliers
        5.3.2    Bargaining Power of Buyers
        5.3.3    Threat of New Entrants
        5.3.4    Threat of Substitutes
        5.3.5    Degree of Rivalry
    5.4    Key Demand Indicators 
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends  
    5.7    Value Chain Analysis
6    Global Biobanking Market Segmentation (2017-2032)
    6.1    Global Biobanking Market (2017-2032) by Material
        6.1.1    Market Overview    
        6.1.2    Population-based Biobanks
        6.1.3    Disease-based Biobanks
        6.1.4    Academic Biobanks
        6.1.5    Hospital-based Biobanks
        6.1.6    Commercial Biobanks
    6.2    Global Biobanking Market (2017-2032) by Sample Type
        6.2.1    Market Overview    
        6.2.2    Blood Products
        6.2.3    Human Tissues
        6.2.4    Nucleic Acids
        6.2.5    Cell Lines
        6.2.6    Biological Fluids
        6.2.7    Others
    6.3    Global Biobanking Market (2017-2032) by Application
        6.3.1    Market Overview    
        6.3.2    Drug Discovery and Development
        6.3.3    Personalized Medicine
        6.3.4    Regenerative Medicine
        6.3.5    Clinical Research
        6.3.6    Forensics
        6.3.7    Others
    6.4    Global Biobanking Market (2017-2032) by Ownership
        6.4.1    Market Overview    
        6.4.2    Public Biobanks
        6.4.3    Private Biobanks
        6.4.4    Hybrid Biobanks
    6.5    Global Biobanking Market (2017-2032) by Source
        6.5.1    Market Overview
        6.5.2    Human Biobanks
        6.5.3    Animal Biobanks
        6.5.4    Plant Biobanks
    6.6    Global Biobanking Market (2017-2032) by End User
        6.6.1    Market Overview
        6.6.2    Biopharmaceutical Companies
        6.6.3    Research and Academic Institutes
        6.6.4    Hospitals
        6.6.5    Contract Research Organizations (CROs)
        6.6.6    Others
    6.7    Global Biobanking Market (2017-2032) by Region
        6.7.1    Market Overview
        6.7.2    North America
        6.7.3    Europe 
        6.7.4    Asia Pacific
        6.7.5    Latin America
        6.7.6    Middle East and Africa
7    North America Biobanking Market (2017-2032)
    7.1    North America Biobanking Market (2017-2032) by Material
        7.1.1    Market Overview    
        7.1.2    Population-based Biobanks
        7.1.3    Disease-based Biobanks
        7.1.4    Academic Biobanks
        7.1.5    Hospital-based Biobanks
        7.1.6    Commercial Biobanks
    7.2    North America Biobanking Market (2017-2032) by Sample Type
        7.2.1    Market Overview    
        7.2.2    Blood Products
        7.2.3    Human Tissues
        7.2.4    Nucleic Acids
        7.2.5    Cell Lines
        7.2.6    Biological Fluids
        7.2.7    Others
    7.3    North America Biobanking Market (2017-2032) by Country
        7.3.1    United States of America
        7.3.2    Canada
8    Europe Biobanking Market (2017-2032)
    8.1    Europe Biobanking Market (2017-2032) by Material
        8.1.1    Market Overview    
        8.1.2    Population-based Biobanks
        8.1.3    Disease-based Biobanks
        8.1.4    Academic Biobanks
        8.1.5    Hospital-based Biobanks
        8.1.6    Commercial Biobanks
    8.2    Europe Biobanking Market (2017-2032) by Sample Type
        8.2.1    Market Overview    
        8.2.2    Blood Products
        8.2.3    Human Tissues
        8.2.4    Nucleic Acids
        8.2.5    Cell Lines
        8.2.6    Biological Fluids
        8.2.7    Others
    8.3    Europe Biobanking Market (2017-2032) by Country
        8.3.1    United Kingdom
        8.3.2    Germany
        8.3.3    France
        8.3.4    Italy
        8.3.5    Others
9    Asia Pacific Biobanking Market (2017-2032)
    9.1    Asia Pacific Biobanking Market (2017-2032) by Material
        9.1.1    Market Overview    
        9.1.2    Population-based Biobanks
        9.1.3    Disease-based Biobanks
        9.1.4    Academic Biobanks
        9.1.5    Hospital-based Biobanks
        9.1.6    Commercial Biobanks
    9.2    Asia Pacific Biobanking Market (2017-2032) by Sample Type
        9.2.1    Market Overview    
        9.2.2    Blood Products
        9.2.3    Human Tissues
        9.2.4    Nucleic Acids
        9.2.5    Cell Lines
        9.2.6    Biological Fluids
        9.2.7    Others
    9.3    Asia Pacific Biobanking Market (2017-2032) by Country
        9.3.1    China
        9.3.2    Japan
        9.3.3    India
        9.3.4    ASEAN
        9.3.5    Australia
        9.3.6    Others
10    Latin America Biobanking Market (2017-2032)
    10.1     Latin America Biobanking Market (2017-2032) by Material
        10.1.1    Market Overview    
        10.1.2    Population-based Biobanks
        10.1.3    Disease-based Biobanks
        10.1.4    Academic Biobanks
        10.1.5    Hospital-based Biobanks
        10.1.6    Commercial Biobanks
    10.2     Latin America Biobanking Market (2017-2032) by Sample Type
        10.2.1    Market Overview    
        10.2.2    Blood Products
        10.2.3    Human Tissues
        10.2.4    Nucleic Acids
        10.2.5    Cell Lines
        10.2.6    Biological Fluids
        10.2.7    Others
    10.3     Latin America Biobanking Market (2017-2032) by Country
        10.3.1    Brazil
        10.3.2    Argentina
        10.3.3    Mexico
        10.3.4    Others
11    Middle East and Africa Biobanking Market (2017-2032)
    11.1     Middle East and Africa Biobanking Market (2017-2032) by Material
        11.1.1    Market Overview    
        11.1.2    Population-based Biobanks
        11.1.3    Disease-based Biobanks
        11.1.4    Academic Biobanks
        11.1.5    Hospital-based Biobanks
        11.1.6    Commercial Biobanks
    11.2     Middle East and Africa Biobanking Market (2017-2032) by Sample Type
        11.2.1    Market Overview    
        11.2.2    Blood Products
        11.2.3    Human Tissues
        11.2.4    Nucleic Acids
        11.2.5    Cell Lines
        11.2.6    Biological Fluids
        11.2.7    Others
    11.3     Middle East and Africa Biobanking Market (2017-2032) by Country
        11.3.1    Saudi Arabia
        11.3.2    United Arab Emirates
        11.3.3    Nigeria
        11.3.4    South Africa
        11.3.5    Others
12    Regulatory Framework
    12.1     Regulatory Overview
        12.1.1    US FDA
        12.1.2    EU EMA
        12.1.3    INDIA CDSCO
        12.1.4    JAPAN PMDA
        12.1.5    Others
13    Patent Analysis
    13.1     Analysis by Type of Patent
    13.2     Analysis by Publication Year
    13.3     Analysis by Issuing Authority
    13.4     Analysis by Patent Age
    13.5     Analysis by CPC Analysis
    13.6     Analysis by Patent Valuation 
    13.7     Analysis by Key Players
14    Grants Analysis
    14.1     Analysis by Year
    14.2     Analysis by Amount Awarded
    14.3     Analysis by Issuing Authority
    14.4     Analysis by Grant Application
    14.5     Analysis by Funding Institute
    14.6     Analysis by Departments
    14.7     Analysis by Recipient Organization 
15    Funding and Investment Analysis
    15.1     Analysis by Funding Instances
    15.2     Analysis by Type of Funding
    15.3     Analysis by Funding Amount
    15.4     Analysis by Leading Players
    15.5     Analysis by Leading Investors
    15.6     Analysis by Geography
16    Partnership  and Collaborations Analysis
    16.1     Analysis by Partnership Instances
    16.2     Analysis by Type of Partnership
    16.3     Analysis by Leading Players
    16.4     Analysis by Geography
17    Supplier Landscape
    17.1     Thermo Fisher Scientific Inc.
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications 
    17.2     Brooks Automation, Inc.
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3     Qiagen N.V. 
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4     Tecan Group Ltd.
        17.4.1     Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5     Hamilton Company
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6     Chart Industries, Inc.
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7     PHC Holdings Corporation
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8     Becton, Dickinson and Company (BD) 
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9     Merck KGaA
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    Panasonic Healthcare Holdings Co., Ltd.
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications 
    17.11    STEMCELL Technologies Inc.
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications 
    17.12    Lifenet Health
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications 
    17.13    Promega Corporation
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisitions
        17.13.5    Certifications 
    17.14    Greiner Bio-One International GmbH
        17.14.1    Financial Analysis
        17.14.2    Product Portfolio
        17.14.3    Demographic Reach and Achievements
        17.14.4    Mergers and Acquisitions
        17.14.5    Certifications 
    17.15    Lonza Group AG
        17.15.1    Financial Analysis
        17.15.2    Product Portfolio
        17.15.3    Demographic Reach and Achievements
        17.15.4    Mergers and Acquisitions
        17.15.5    Certifications 
List not exhaustive
18    Global Biobanking  Market – Distribution Model (Additional Insight)
    18.1     Overview 
    18.2     Potential Distributors 
    18.3     Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1     Very Small Companies
    20.2     Small Companies
    20.3     Mid-Sized Companies
    20.4     Large Companies
    20.5     Very Large Companies
21    Payment Methods (Additional Insight)
    21.1     Government Funded
    21.2     Private Insurance
    21.3     Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

 

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Key Questions Answered in the Report

The market attained a value of about USD 72.1 billion in 2023 driven by the increased genomic research activities aimed at discovering innovative therapeutic interventions across the globe.

The market is anticipated to grow at a CAGR of 6.89% during the forecast period of 2024-2032, likely to reach a market value of USD 131.1 billion by 2032.

Advancements in biobank data analysis such as the integration of artificial intelligence and machine learning are fuelling the market demand. 

One of the significant trends in the market are the rising financial support from both private and government sectors to improve the infrastructure and database capabilities of biobanks. In October 2023, the United Kingdom Biobank received EUR 16 million, coupled with another EUR 25 million contribution from the government. These investments are expected to aid the expansion of biobank’s health data and accelerate research.

Based on the material, the market is segmented into population-based biobanks, disease-based biobanks, academic biobanks, hospital-based biobanks, and commercial biobanks.

By sample type, the market is divided into blood products, human tissues, nucleic acids, cell lines, biological fluids, and others.

The market breakup by ownership in the global biobanking market includes public biobanks, private biobanks, and hybrid biobanks.

The market segmentation by source includes human biobanks, animal biobanks, and plant biobanks. 

Major end users of the market include biopharmaceutical companies, research and academic institutes, hospitals, contract research organizations (CROs), and others.

Applications of the market include drug discovery and development, personalized medicine, regenerative medicine, clinical research, forensics, and others. 

The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.

Key players involved in the market are Thermo Fisher Scientific Inc., Brooks Automation, Inc., Qiagen N.V., Tecan Group Ltd., Hamilton Company, Chart Industries, Inc., PHC Holdings Corporation, Becton, Dickinson and Company (BD), Merck KGaA, Panasonic Healthcare Holdings Co., Ltd., STEMCELL Technologies Inc., Lifenet Health, Promega Corporation, Greiner Bio-One International GmbH, and Lonza Group AG.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER